Centessa Pharmaceuticals Files 8-K

Ticker: CNTA · Form: 8-K · Filed: Jan 8, 2025 · CIK: 1847903

Centessa Pharmaceuticals PLC 8-K Filing Summary
FieldDetail
CompanyCentessa Pharmaceuticals PLC (CNTA)
Form Type8-K
Filed DateJan 8, 2025
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: corporate-filing, 8-K, disclosure

Related Tickers: CNTA

TL;DR

Centessa Pharma filed an 8-K on Jan 8, 2025, with corporate details.

AI Summary

Centessa Pharmaceuticals plc filed an 8-K on January 8, 2025, reporting a current event. The filing details the company's incorporation in England and Wales and provides its principal executive office address in Altrincham, Cheshire, United Kingdom. It also lists the company's IRS number and SEC file number.

Why It Matters

This filing serves as an official notification of current events for Centessa Pharmaceuticals, providing key corporate and contact information to the public and investors.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently poses a significant risk.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

This 8-K filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting a current event for Centessa Pharmaceuticals plc.

When was the earliest event reported in this filing?

The earliest event reported in this filing occurred on January 8, 2025.

In which jurisdiction is Centessa Pharmaceuticals plc incorporated?

Centessa Pharmaceuticals plc is incorporated in England and Wales.

What is the company's principal executive office address?

The company's principal executive office is located at 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, United Kingdom.

What is the SEC file number for Centessa Pharmaceuticals plc?

The SEC file number for Centessa Pharmaceuticals plc is 001-40445.

Filing Stats: 591 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-01-08 07:00:18

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure The Company from time to time presents and/or distributes slide presentations to the investment community at various industry and other conferences to provide updates and summaries of its business. The Company is posting a copy of its current corporate slide presentation to the "Investors" portion of its website at www.centessa.com/events-presentations. These slides are attached to this Current Report on Form 8-K as Exhibit 99.1. The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibits 99.1.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. 99.1 Corporate Presentation as of January 8, 2025 104 Cover Page Interactive Data (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 8, 2025 By: /s/ Saurabh Saha Name: Saurabh Saha, M.D., Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing